TrialLipids in health and disease2017

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.

Tamio Teramoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.